Adaptive Biotechnologies
Commercial-stage biotechnology company whose clonoSEQ NGS assay is widely used for measurable residual disease assessment in hematologic malignancies.
Hematologic Malignancies · Immune-receptor NGS / MRD · Commercial
Commercial-stage biotechnology company whose clonoSEQ NGS assay is widely used for measurable residual disease assessment in hematologic malignancies.
Hematologic Malignancies · Immune-receptor NGS / MRD · Commercial